Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Sudbury, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa for ALLN-346. The Company’s wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.

Industry: Biological Products, (No Diagnostic Substances) Peers: ACTAVIA LIFE SCIENCES, INC. GlobeStar Therapeutics Corp GridAI Technologies Corp International Stem Cell Corp Histogen Inc. NovAccess Global Inc.